Glenmark Life Sciences Balance Sheet Health
Financial Health criteria checks 6/6
Glenmark Life Sciences has a total shareholder equity of ₹25.4B and total debt of ₹0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₹30.8B and ₹5.5B respectively. Glenmark Life Sciences's EBIT is ₹5.5B making its interest coverage ratio -52.2. It has cash and short-term investments of ₹4.5B.
Key information
0%
Debt to equity ratio
₹0
Debt
| Interest coverage ratio | -52.2x |
| Cash | ₹4.46b |
| Equity | ₹25.38b |
| Total liabilities | ₹5.46b |
| Total assets | ₹30.85b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: GLS's short term assets (₹21.0B) exceed its short term liabilities (₹4.6B).
Long Term Liabilities: GLS's short term assets (₹21.0B) exceed its long term liabilities (₹826.5M).
Debt to Equity History and Analysis
Debt Level: GLS is debt free.
Reducing Debt: GLS has no debt compared to 5 years ago when its debt to equity ratio was 453.5%.
Debt Coverage: GLS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GLS has no debt, therefore coverage of interest payments is not a concern.